ASCO22: sacituzumab govitecan yields promising results for HR+/HER2- metastatic breast cancer

Results from the TROPiCs-02 Phase III trial have recently been presented at the Annual Society of Clinical Oncology (ASCO) Meeting 2022 (3–7 June, IL, USA). The TROPiCs-02 trial is investigating Trodelvy® (sacituzumab govitecan) vs treatment of physician’s choice for HR+/HER2- advanced breast cancer. Sacituzumab govitecan demonstrated improved median progression-free survival (PFS) by 34% (5.5 vs. 4.0 months) when compared to standard chemotherapy, in cases where more than 50% of patients had received three or more lines of chemotherapy. The trial included 543 patients with HR+/HER2- metastatic breast cancer who had been treated with endocrine therapy, CDK4/6 inhibitors, and 2–4 chemotherapy...